Страна: США
мова: англійська
Джерело: NLM (National Library of Medicine)
METOPROLOL SUCCINATE (UNII: TH25PD4CCB) (METOPROLOL - UNII:GEB06NHM23)
Northwind Pharmaceuticals
METOPROLOL SUCCINATE
METOPROLOL TARTRATE 100 mg
ORAL
PRESCRIPTION DRUG
1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety
Metoprolol succinate extended-release tablets USP, 100 mg are white to off-white, round shaped, film-coated tablets, debossed with “M” and “3” separated by breakline on one side and plain on other side. They are supplied in bottles of 30, 60, 100, 500 and unit dose packages of 100 (10x10). Bottles of 30 NDC 55111-468-30 Bottles of 60 NDC 55111-468-60 Bottles of 100 NDC 55111-468-01 Bottles of 500 NDC 55111-468-05 Unit dose packages of 100 (10x10) NDC 55111-468-78 Metoprolol succinate extended-release tablets USP, 200 mg are white to off-white, oval shaped film-coated tablets, debossed with “M” and “4” separated by breakline on one side and plain on other side. They are supplied in bottles of 30, 60, 100, 500 and unit dose packages of 100 (10x10). Bottles of 30 NDC 55111-469-30 Bottles of 60 NDC 55111-469-60 Bottles of 100 NDC 55111-469-01 Bottles of 500 NDC 55111-469-05 Unit dose packages of 100 (10x10) NDC 55111-469-78 Store at 20°-25°C (68°-77°F); [See USP Controlled Room Temperature.] Please review the manufacturer's complete drug information available from the FDA at www.fda.gov Permanent Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71c1d33e-be6f-6d59-b715-45075445891a
Abbreviated New Drug Application
METOPROLOL SUCCINATE ER- METOPROLOL SUCCINATE ER TABLET, EXTENDED RELEASE NORTHWIND PHARMACEUTICALS ---------- METOPROLOL SUCCINATE ER 100MG INDICATIONS AND USAGE 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populati Прочитайте повний документ